281 related articles for article (PubMed ID: 27224743)
1. Proton pump inhibitors and osteoporosis.
Andersen BN; Johansen PB; Abrahamsen B
Curr Opin Rheumatol; 2016 Jul; 28(4):420-5. PubMed ID: 27224743
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Fournier MR; Targownik LE; Leslie WD
Maturitas; 2009 Sep; 64(1):9-13. PubMed ID: 19674854
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term proton pump inhibitors on bone mineral density.
Romdhane H; Ayadi S; Elleuch N; Abdelghani K
Tunis Med; 2018 Mar; 96(3):193-197. PubMed ID: 30325487
[TBL] [Abstract][Full Text] [Related]
5. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools.
Sobel RE; Bate A; Marshall J; Haynes K; Selvam N; Nair V; Daniel G; Brown JS; Reynolds RF
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):332-339. PubMed ID: 29392851
[TBL] [Abstract][Full Text] [Related]
6. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
7. The relationship among proton pump inhibitors, bone disease and fracture.
Targownik LE; Leslie WD
Expert Opin Drug Saf; 2011 Nov; 10(6):901-12. PubMed ID: 21599546
[TBL] [Abstract][Full Text] [Related]
8. [Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].
Maléth J; Hegyi P
Orv Hetil; 2013 Jun; 154(26):1005-9. PubMed ID: 23800385
[TBL] [Abstract][Full Text] [Related]
9. The effect of proton pump-inhibiting drugs on mineral metabolism.
Insogna KL
Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S2-4. PubMed ID: 19262542
[TBL] [Abstract][Full Text] [Related]
10. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
McGowan B; Bennett K; Barry M
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
[TBL] [Abstract][Full Text] [Related]
11. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
12. The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture-results of a large observational cohort study.
Fitzpatrick D; Lannon R; Laird E; Ward M; Hoey L; Hughes CF; Strain JJ; Cunningham C; McNulty H; Molloy AM; McCarroll K
Osteoporos Int; 2023 Nov; 34(11):1917-1926. PubMed ID: 37530847
[TBL] [Abstract][Full Text] [Related]
13. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Targownik LE; Lix LM; Leung S; Leslie WD
Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
[TBL] [Abstract][Full Text] [Related]
14. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
15. Chronic proton pump inihibitor therapy and calcium metabolism.
Yang YX
Curr Gastroenterol Rep; 2012 Dec; 14(6):473-9. PubMed ID: 23054811
[TBL] [Abstract][Full Text] [Related]
16. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
Maggio M; Lauretani F; Ceda GP; De Vita F; Bondi G; Corsonello A; Cattabiani C; Lattanzio F; Ruggiero C; Nouvenne A; Meschi T; Bandinelli S; Ferrucci L
Bone; 2013 Dec; 57(2):437-42. PubMed ID: 24076021
[TBL] [Abstract][Full Text] [Related]
17. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
18. The relationship between long-term proton pump inhibitor therapy and skeletal frailty.
Lau AN; Tomizza M; Wong-Pack M; Papaioannou A; Adachi JD
Endocrine; 2015 Aug; 49(3):606-10. PubMed ID: 25948072
[TBL] [Abstract][Full Text] [Related]
19. Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength.
Hussain MS; Mazumder T
J Basic Clin Physiol Pharmacol; 2022 Sep; 33(5):567-579. PubMed ID: 34687598
[TBL] [Abstract][Full Text] [Related]
20. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
